Clinical utility of a 1.5 T magnetic resonance imaging-guided linear accelerator during conventionally fractionated and hypofractionated prostate cancer radiotherapy
Authors:
Open Access
- 16 August 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 909402
Abstract
Purpose: To report our initial experience with 1.5 T magnetic resonance imaging (MRI) linear accelerator (LINAC) in prostate cancer radiotherapy in terms of its use in a radiation oncology clinic.Methods: The medical records of 14 prostate cancer patients treated with MRI-guided radiotherapy were retrospectively evaluated. The fraction time, adapt-to-position (ATP):adapt-to-shape (ATS) usage rate, machine-associated treatment interruption rate, median gamma pass rate, the percentage of planning target volume receiving at least 95% of the prescription dose coverage value of each ATS fraction, the effect of the learning curve on the fraction time and radiation-related acute gastrointestinal and genitourinary toxicities were evaluated.Results: Fourteen patients have completed their treatment receiving a total of 375 fractions. Six patients (42%) were treated with the moderately hypofractionated regimen, five patients (36%) with conventionally fractionated, and three patients (22%) with the ultra-hypofractionated radiotherapy regimens. The ATP : ATS usage ratio was 3:372. The median fraction time was 46 min (range, 24-81 min). For the 3%/3 mm criterion, median gamma pass rate was 99.4% (range, 94.6–100%). Machine-related treatment interruptions were observed in 11 (2.9%) of 375 fractions, but this interruption rate decreased from 4.1% to 0.8%, after an upgrade. Three patients (22%) had gastrointestinal and five patients (36%) had genitourinary toxicity. No ≥grade 3 toxicity was observed.Conclusion: 1.5 T MRI-LINAC device could be used as a conventional LINAC device, when the conditions of the radiotherapy center are appropriate. MRI-guided prostate radiotherapy is safe and feasible, and high-quality studies with a larger number of patients and long-term results are needed to better evaluate this new technology.Keywords
This publication has 15 references indexed in Scilit:
- Prostate intrafraction motion during the preparation and delivery of MR-guided radiotherapy sessions on a 1.5T MR-LinacRadiotherapy and Oncology, 2020
- 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatmentRadiation Oncology, 2020
- Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trialThe Lancet Oncology, 2019
- Prostate cancer – Advantages and disadvantages of MR-guided RTClinical and Translational Radiation Oncology, 2019
- Adaptive radiotherapy: The Elekta Unity MR-linac conceptClinical and Translational Radiation Oncology, 2019
- First clinical experiences with a high field 1.5 T MR linacActa Oncologica, 2019
- Magnetic Resonance Imaging-Guided Adaptive Radiation Therapy: A “Game Changer” for Prostate Treatment?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2018
- Fast online replanning for interfraction rotation correction in prostate radiotherapyMedical Physics, 2017
- Repeated diffusion MRI reveals earliest time point for stratification of radiotherapy response in brain metastasesPhysics in Medicine & Biology, 2017
- Use of Normal Tissue Complication Probability Models in the ClinicInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010